Meeting
2011 Gastrointestinal Cancers Symposium
A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer.
Authors
Raymond Wadlow
Massachusetts General Hospital
Raymond Wadlow , Aram Hezel , Brian Wolpin , Jill Allen , Eunice Kwak , Andrew Zhu , David Ryan , Jeffrey Clark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT00842257
Citation
J Clin Oncol 29: 2011 (suppl 4; abstr 428)
Abstract #
428
Poster Bd #
A73
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2018 Gastrointestinal Cancers Symposium
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.
First Author: Tomohiro Nishina
Poster
2017 ASCO Annual Meeting
Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.
First Author: Jeremy David Shapiro